今日快报！姚记科技大手笔分红！每10股派9元现金，6月20日除权除息

姚记科技大手笔分红！每10股派9元现金，6月20日除权除息

深圳 - 2024年6月14日，据智通财经报道，姚记科技(002605.SZ)今日发布公告，拟向全体股东每10股派发9元人民币(含税)现金红利，共计派发现金约1.8亿元。除权除息日为2024年6月20日。

此次分红派息是姚记科技对投资者回报的体现，也彰显了公司对未来发展前景的信心。 2023年，公司实现营业收入42.3亿元，同比增长18.5%；归属于上市公司股东的净利润5.2亿元，同比增长22.3%。公司业绩稳健增长，盈利能力持续增强，为本次大手笔分红奠定了坚实基础。

**姚记科技主要从事光学薄膜材料的研发、生产和销售，产品广泛应用于智能手机、平板电脑、笔记本电脑、电视等电子产品。**近年来，随着智能手机等消费电子产品需求的快速增长，公司业务发展迅速，盈利能力不断提升。

**展望未来，**姚记科技将继续加大技术研发投入，不断提升产品质量和竞争力，积极拓展新应用领域，努力为股东创造更大的价值。公司表示，将坚持以客户为中心，以创新为驱动，致力于成为全球领先的光学薄膜材料供应商。

**除权除息是指股份变动日后的股东才有权享有此次现金分红。**投资者如欲享有姚记科技本次现金分红权，需在除权除息日前持有公司股票。

**具体而言，**投资者可在2024年6月20日(含当日)之前买入姚记科技股票，并在当日或之后继续持有，即可享有本次现金分红权。若投资者在6月20日之后买入或卖出姚记科技股票，则将不享有本次现金分红权。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.